Panacea Biotech share price has plunged 6% and is presently trading at Rs 233.7.
Meanwhile, the BSE HEALTHCARE index is at 42,578.0 (down 0.4%).
Among the top losers in the BSE HEALTHCARE index today are ALEMBIC PHARMA (down 2.8%) and SUN PHARMA ADV. RES. (down 1.8%).
AJANTA PHARMA (up 2.9%) and ERIS LIFESCIENCES (up 2.5%) are among the top gainers today.
Over the last one year, Panacea Biotech has moved up from Rs 138.6 to Rs 233.7, registering a gain of Rs 95.1 (up 68.6%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,859.6 to 42,578.0, registering a gain of 52.8% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 136.4%), Glenmark Pharma (up 122.3%) and SUVEN PHARMACEUTICALS (up 108.7%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 82,007.9 (up 0.3%).
The top gainers among the BSE Sensex today are Bajaj Finance (up 2.6%) and Bajaj Finserv (up 2.3%). The most traded stocks in the BSE Sensex are Tata Steel and HDFC Bank.
In the meantime, NSE Nifty is at 25,098.7 (up 0.2%). Bajaj Finance and Bajaj Finserv are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,996.6 to 82,007.9, registering a gain of 17,011.3 points (up 26.2%).
Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.
For the year ended March 2023, Panacea Biotech reported 103.1% decrease in net profit to Rs -337 million compared to net profit of Rs 10,783 million during FY22. Revenue of the company fell 30.4% to Rs 4,599 million during FY23.
The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -50.5.
Equitymaster requests your view! Post a comment on "Panacea Biotech Plunges 6%; BSE HEALTHCARE Index Down 0.4%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!